Minutes:

Guideline Development Group Meeting

Place:  Boardroom, Level 5, 180 Great Portland Street, London, W1W 5QZ

Present:

Philip Conaghan (Chair)
Mark Porcheret (MP)
Elspeth Wise (EW)
Ian Bernstein (IB)
Fraser Birrell (FB)
Michael Doherty (MD)
Peter Kay (PK)
Rob Middleton (RM)
Brian Lucas (BL)
Krysia Dziedzic (KD)
Weiya Zhang (WZ)
Erika Baker (EB)
Tony Whiting (TW)
Jo Cumming (JC)

Dave Wonderling, Health Economics Lead (DW)
Sara Buckner, Research Fellow (SB)
Smita Padhi, Research Fellow (SP)
Vanessa Delgado Nunes, Guideline Lead and Senior Research Fellow (VDN)
Sue Latchem, Guideline Lead and Operations Director (SL)
Paul Miller, Information Scientist (PM)

In attendance from NICE:

Claire Turner, NICE Guidelines Commissioning Manager (CT)
Barbara Meredith, NICE Patient and Public Involvement Unit Project Manager (AM) (BM)

Apologies:

None for this meeting

Observers:

Margaret Constanti, Health Economist (MC)

Declarations of Interest
PC
Declared a personal non pecuniary interests:
He is since 2008 the Chair for the Arthritis Research UK Osteoarthritis Clinical Studies Group.
Responsible for national OA clinical research consensus priority setting and promotion of investigator
initiated studies. The funding goes to his department.
He is since 2010 a scientific committee member SORT study (Survey of Osteoarthritis Real World
Therapies), which is an academic collaboration funded by Merck to his department.
He is also the principal investigator on analysis of GPRD database of how GPs prescribe for OA and
trends before and after last NICE guidance. Again, this is an academic collaboration. Not product specific
and no funding involved. Astra Zeneca product in this field was not licensed for the period of the analysis.
He is on the steering committee member (not PI) on randomised trial of combination pill versus celecoxib
200mg. Trial requested by Spanish regulatory authorities. Bioiberica. This combination pill is not licensed
in UK and he doesn’t know if application is being made. This would therefore not be under NICE
consideration and would be willing to withdraw if such application is made.
In May 2011 he was a Speaker at the Spanish Society of Rheumatology, talk entitled “Osteoarthritis
Imaging: Diagnostic and Predictive Value”, and received a one time personal payment from Bioiberica.
He was also a speaker at RCP London, talk entitled “OA Overview – state of the art lecture” which was
sponsored by mundipharm.
Since March 2012 he has also acted as an advisor for Arthritis Care OA Nation 2012 report – a survey of
OA impact in the community, which is unrelated to the guideline scope.
Declared a personal non specific pecuniary interest: In March 2012 he had a collaboration on
development of bone-related therapy for OA and received a personal payment for advisory meetings from
Servier. Strontium is not part of the guideline update scope.
IB
Declared a personal pecuniary interest: He received a consultancy fee in June 2011 for acting as a clinical
advisor to InHealth Ltd with respect to their tender application to run NHS musculoskeletal services in
South Tyneside NHS Trust. He received a fee in September 2011 for acting as a course organiser funded
by InHealth Ltd, to run a GP education programme about musculoskeletal services.
He is paid an NHS salary for service development work including acting as an MSk clinical advisor to:
MD
Declared personal pecuniary interest: Dec 2011: Advisory Board Servier (strontium in OA) – non-specific
Sept 2011: Advisory Board Novartis (low dose, over-the-counter diclofenac versus paracetamol and
placebo for OA) – non-specific
Co-author of BMJ Evidence Series on OA (unpaid)
Member of EULAR Guideline Development group for non-pharmacological management of knee and hip
OA, 2011-2012 (unpaid)
OARSI primer on OA (unpaid)
Co-Editor of OUP Osteoarthritis (3rd Ed – in preparation) (shared royalties from sales)
Member of Arthritis Research UK OA Clinical Study Group 2007-now (unpaid).
MP
Declared a personal non-pecuniary interest: He works as a Lecturer in General Practice at the Arthritis
Research UK Primary Care Centre at Keele University. In this role he writes, presents and publishes
academic papers on osteoarthritis, is invited to speak at academic and educational meetings on
osteoarthritis (most recently for the EULAR Conference - June 2012 - on the role of GPs in supporting the
self-management of osteoarthritis) and writes and publishes educational articles (most recently for Arthritis
Research UK - edition of Hands on osteoarthritis and an article for their Arthritis Today magazine on
osteoarthritis). He is currently a member of the panel advising Arthritis Care on undertaking and
disseminating the findings of their OA Nation survey.
Declared a non personal pecuniary interest: The Centre receives funding from various funding bodies but
not from any pharmaceutical companies. He does not receive speaker fees for presenting at conferences
or other meetings but is reimbursed travel and accommodation expenses. His role with Arthritis Care is
unpaid.
TW
Declared a personal non pecuniary interest: He is a member of the Governing Body of Sheffield LINk, of
his local GP Practice Patient Group, of a Cardiac network user group and of the north Sheffield Patient
group. He is an occasional representative service user / carer / lay member to the Sheffield University
Psychology Unit on terms of lecturing / advisor / supporting.
Family related interest: His elder son is a Consultant Anaesthetist in Sheffield.

**RM**

Declared a personal pecuniary interest: Consultancy services and implant design to Orthopedic Implant Industry [Zimmer, DePuy, Lima, WG Healthcare, Finsbury].

Declared personal non-pecuniary interests: Principle Investigator or Participating Investigator in research trials into the outcomes of hip replacements sponsored by Implant manufactures (Zimmer, Smith & Nephew, Lima).

Lectures, Podcasts, Publications, and Workshops Nationally and Internationally on Enhanced Recovery, Rapid Improvement Programmes in Orthopaedics, Hip Replacement, Osteoarthritis and Exercise.

Orthopaedic Surgeon with NHS and Private Practice in the surgical treatment of Osteoarthritis.

Director of Healthdecoded a healthcare management consultancy working in hospitals to improve quality and efficiency of care.

**FB**

Declared non personal pecuniary interests: commercial trial recruitment in osteoarthritis 2008-2011 servier . Speaker honoraria 2011 Amgen, Menarini

Chaired steering conference for IQ Leaders – generic leadership skills programme for high achieving new consultants 2011-Litms Pfizer

Chairing national advisory board on glucosamine sulphate oral power 5/5/11HFA health care

Expert consultant for MHRA appeal on civamide 8/4/11Winston Pharmaceuticals

All honoraria have been put into research accounts.

**BL**

Declared personal non pecuniary interest: Chair of Royal College of Nursing’s Society of Orthopaedic and Trauma Nursing (unpaid and in own time)

Also on the editorial board of the International Journal of Orthopaedic and Trauma Nursing.

**EW**

Declared a non personal pecuniary interest: Received an educational grant for £1000 towards travel/accommodation to the American College of Rheumatology Meeting from Pfizer Speaker fees/travel/accommodation from Pfizer UK for a European Primary Care Meeting Locum fees/travel/accommodation from Napp.

Declared personal pecuniary interests: Chair the BMJ musculoskeletal masterclass which includes a sponsored presentation. Does not receive any money from the sponsors and receives travel/accommodation/locum fees and speaker fees from BMJ publishing only.

Has arranged a local meeting for the Royal College of General Practitioners which was sponsored. Did not receive any money or expenses for the meeting.

Is a member of a local GPSI group which receives support from Pfizer (i.e. they arrange a room for the meeting). She will be receiving travel/accommodation and speaker fees (which will mainly go towards her locum expenses) from Servier for a local advisory board and an educational meeting for their staff.

Is a member of the Primary Care Rheumatology Society which receives funding from different drug companies.

**JC**

Declared non-personal pecuniary interests: Arthritis Care as received educational grants from Roche with regards to publications for children with JIA and also a school bag competition. None of these involved myself or my former department the Helplines service.

Arthritis Care received a one off honorarium for a speaking engagement organised by Astra Zeneca. This did not come to me or my department.

2011 -2012 -

Arthritis Care has received educational grants from Pfizer, NAPP, Sanofi and Astra Zeneca to conduct a survey of people living with OA across the UK. This has been an independent project within Arthritis Care and has not attracted any funding to myself individually or to my former or current departments.

Arthritis Care has recently received an educational grant relating to work with Servier which has included a one off presentation me. This has not come either to me or my current department

**KD**

Declared personal pecuniary interest: Has two conference presentations at the forthcoming EULAR 6-9 June 2012 conference. As an invited speaker she has travel, accommodation and the conference fee paid
and accommodation for an accompanying person. It relates to research for a study where she already holds a grant for a funded project implementing the NICE OA guidelines in primary care - the MOSAICS study Managing osteoarthritis in consultations.

PK
Declared non-personal pecuniary interests: Part of a large specialist Orthopaedic and Rheumatology Hospital (Wrightington) providing patient services for osteoarthritis. The Institution has and continues to receive research funding from orthopaedic implant and pharmacological companies for patients suffering from Osteoarthritis.

Declared Personal non-pecuniary interests: President of the British Orthopaedic Association (Until Sept 2011) who’s aims are

- The advancement for the public benefit of the Science, Art and Practice of Orthopaedic Surgery with the aim of bringing relief to patients of all ages suffering from the effects of injury or disorders of the musculoskeletal system.

As a trustee of the BOA, a principle member of the ARMA who’s aims are

- Raise awareness of the need for high quality services for those with arthritis and other musculoskeletal conditions
- Promote the development of treatment, prevention, rehabilitation and relief
- Foster co-operation, understanding and mutual support between all individuals and organisations concerned with these conditions
- Provide a forum for the exchange of ideas and information between member organisations

Vice chair of the Northwest Musculoskeletal research Network

WZ
Declared personal non-pecuniary interests:

- Member of the Arthritis Research UK Implementation Fellowship Committee (2011 to 2015) - unpaid
- Member of the Osteoarthritis & Cartilage Editorial Board - unpaid
- Member of the Advisory Board for Cochrane Musculoskeletal Disease Group - unpaid
- Lead investigator of the OARSI Treatment Guidelines - 2006 to 2011 with a grant of $10,000 annually for monitoring and updating research evidence in OA
- Co-author for the BMJ Clinical Evidence for OA – unpaid

Declared personal pecuniary interests:

- Invited lecture on "Is placebo a possible therapy for OA?" for the 13th Physiatric Summer School - Placebo effects in musculoskeletal disorders, 16-17 August 2012 Helsinki Finland, travel and hotel paid by the Rehabilitation ORTON Foundation.

EB
Had nothing to declare.

VDN
Declared a family interest. Her partner is director of a health economics consultancy company which receives payment from the pharmaceutical industry and other consultancy companies.

No actions were taken following these declarations and none of the GDG members withdrew as this was an introductory meeting and therefore no evidence or recommendations were to be discussed.

1. The chair of the OA guideline, Philip Conaghan, welcomed the group to the first meeting of this GDG. The GDG members introduced themselves.

2. Each of the following presentations were given:
The NCGC and its guideline programme – Vanessa Delgado Nunes. At the end, a full group discussion was held regarding the GDG’s declarations of interest.

- Working with NICE – Claire Turner
- Patient and carer involvement – Barbara Meredith
- Searching for the evidence – Paul Miller
- Reviewing the evidence – Sara Buckner and Smita Padhi
- Health economics – Dave Wonderling

3. Sara Buckner and Smita Padhi presented a worked example of an evidence review, which contained the findings on the use of warfarin in people with IPF.

4. The Chair presented the scope to the GDG.

5. The GDG were asked to provide feedback on a proposed set of review questions ahead of the meeting. They discussed each in turn again at the meeting and as the session overran, it was decided that the questions would be revisited at GDG meeting 2.

6. VDN asked the GDG whether they were aware of any professionals that would be willing to join the GDG for the following roles: elderly care specialist, pain consultant, occupational health and a radiologist.

The meeting closed at 16.30hrs.

**Date, time and venue of the next meeting**

16th April 2012, 10:30 – 16:30hrs.